Last reviewed · How we verify
PPAR alpha
At a glance
| Generic name | PPAR alpha |
|---|---|
| Sponsor | Eli Lilly and Company |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
- Elevated liver enzymes
- Gastrointestinal discomfort
Key clinical trials
- Evaluation of Possible Safety and Efficacy of Fenofibrate in the Prophylaxis of Doxorubicin Induced Cardiotoxicity in Breast Cancer Patients (PHASE2)
- Genetic-Dependent Cardiovascular Response to PPAR-Alpha Agonist Fenofibrate (NA)
- OEA for Targeting Lipid Metabolism in GWI (NA)
- Pharmacologic Approaches to Preventing Primary Sclerosing Cholangitis Recurrence After Liver Transplantation (PHASE2)
- The Role of Acute Combined PPAR Alpha and Gamma Stimulation on Insulin Action in Humans (PHASE4)
- Real-World Evaluation of Omarigliptin for Type 2 Diabetes Meliitus in Bangladesh (PHASE4)
- Comparison of Repetitive Magnetic Stimulation and Exercise on Quadriceps Function in COPD (NA)
- Acute and Long-Term Outcome Investigations of Fenofibrate on Severely Burned Patients (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PPAR alpha CI brief — competitive landscape report
- PPAR alpha updates RSS · CI watch RSS
- Eli Lilly and Company portfolio CI